VYVGART was well-tolerated with a safety profile consistent with the established profile of VYVGART in patients with AChR-Ab seropositive gMG and other indications. No new safety concerns were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback